ST. CHARLES, Mo., Jan. 16, 2021 /PRNewswire-PRWeb/ -- Eurofins
Bioanalytical Services, a member of Eurofins BioPharma Services,
Laboratory Testing division, announces the launch of a Surrogate
Virus Neutralization Test (sVNT) antibody assay against the
SARS-CoV-2-virus. An alternative to conventional testing with a
live virus, this assay is the first neutralizing antibody serology
test authorized by the FDA as emergency use authorization (EUA).
This innovative assay detects the presence of neutralizing/blocking
antibodies against SARS-CoV-2 virus, that block the interaction
between the receptor-binding domain (RBD) of the viral spike
glycoprotein with the ACE2 cell surface receptor.
Current testing methods, such as PCR, determine whether someone
is actively infected by confirming the presence of viral material
or IgG/IgM antibodies that detect (binding and blocking) induced
immune response from exposure to the virus. Being an ELISA
methodology, the in-house, fully validated surrogate virus
neutralization test (sVNT) is amenable to high-throughput testing,
at a lower analytical cost and requires no extended validation
timelines for our client base. It also removes the obstacle faced
by many COVID-19 development programs, by eliminating the
requirement for a biosafety level 3 containment.
The advantage over historic antibody IgG/IgM tests is that this
new gold standard assay tests for neutralizing antibodies (versus
binding antibodies), by confirming neutralizing function without
the need for a secondary antibody and is isotype and species
independent.
Eurofins BioPharma Services' scientific expertise and breadth of
testing capabilities places the company at the forefront in
supporting clients' mission to accelerate COVID-19
therapeutic/vaccine development and put an end to this crisis.
Combined with the multi-continent footprint and global logistics of
specimen management experience of our Eurofins Central Laboratory
division, we can provide region specific solutions, while still
retaining our Center of Excellence
in St. Charles, MO.
Eurofins Bioanalytical Services is a leader in bioanalytical
solutions for biologics, providing nearly 20 years of
industry-leading scientific expertise. As a division of the
Eurofins Scientific Group, our sole focus is in pre-clinical and
clinical laboratory analysis. With state-of-the-art, testing
facilities in St. Charles, MO,
USA, Eurofins Bioanalytical Services develops, transfers and
validates large molecule PK/TK, immunogenicity and biomarker assays
to our client's specifications. With industry-leading capacity,
capabilities range from a single plate to large multinational Phase
III and IV clinical trials, in a broad range of therapeutic
indications, including vaccines and COVID-19. Eurofins has the
capacity to handle variable sample numbers and large volumes to
meet the needs of clients.
Notes for Editors:
For more information, please visit http://www.eurofins.com or
contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Kristen Galkowski
Eurofins Bioanalytical Services
Email: bioanalyticalinfo@eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter
"Eurofins" or "the Group"), believes it is the global leader in
food, environmental, pharmaceutical and cosmetics products testing
and in agroscience CRO services. It is also one of the global
independent market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, CDMO,
advanced material sciences and in the support of clinical studies.
In addition, Eurofins is one of the leading global emerging players
in esoteric and molecular clinical diagnostic testing. With over
50,000 staff across a network of more than 900 independent
companies in over 50 countries generally specialised by end client
markets and operating more than 800 laboratories, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services. The Group's
objective is to provide its customers with high-quality and
innovative services, accurate results on time and, when requested,
expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and a very large
range of testing methods.
As one of the most innovative and quality-oriented international
groups in its industry, Eurofins is ideally positioned to support
its clients' increasingly stringent quality and safety standards
and the increasing demands of regulatory authorities and healthcare
practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Media Contact
Kristen Galkowski, Eurofins
Bioanalytical Services, 6363627166,
KristenGalkowski@eurofins.com
SOURCE Eurofins Bioanalytical Services